EA201690680A1 - Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма - Google Patents
Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гаммаInfo
- Publication number
- EA201690680A1 EA201690680A1 EA201690680A EA201690680A EA201690680A1 EA 201690680 A1 EA201690680 A1 EA 201690680A1 EA 201690680 A EA201690680 A EA 201690680A EA 201690680 A EA201690680 A EA 201690680A EA 201690680 A1 EA201690680 A1 EA 201690680A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gamma
- interferon
- minicoles
- aimed
- loaded
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Представлены композиции и способы для лечения злокачественных опухолей. Методология влечет за собой, например, введение пациенту с раком первой композиции, содержащей множество полученных из бактерий интактных миниклеток или интактных убитых бактериальных клеток, каждая из которых содержит противораковое средство и несет биспецифический лиганд на поверхности, лиганд, обладающий специфичностью к компоненту клетки млекопитающего, и второй композиции, содержащей интерферон-гамма (IFN-гамма) или средство, которое повышает экспрессию IFN-гамма у индивидуума. Композиции включают первую композицию и вторую композицию, как описано, необязательно с дополнительным противораковым средством.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361887258P | 2013-10-04 | 2013-10-04 | |
PCT/IB2014/002824 WO2015049589A1 (en) | 2013-10-04 | 2014-10-03 | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690680A1 true EA201690680A1 (ru) | 2016-07-29 |
EA032740B1 EA032740B1 (ru) | 2019-07-31 |
Family
ID=52777107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690680A EA032740B1 (ru) | 2013-10-04 | 2014-10-03 | Способ лечения опухоли у индивидуума и набор для осуществления способа |
Country Status (17)
Country | Link |
---|---|
US (2) | US9731011B2 (ru) |
EP (1) | EP3052122A4 (ru) |
JP (1) | JP6538031B2 (ru) |
KR (1) | KR102433719B1 (ru) |
CN (1) | CN105658233B (ru) |
AP (1) | AP2016009153A0 (ru) |
AU (1) | AU2014330895B2 (ru) |
BR (1) | BR112016007100A2 (ru) |
CA (1) | CA2926161C (ru) |
EA (1) | EA032740B1 (ru) |
HK (1) | HK1223281A1 (ru) |
IL (1) | IL244851B (ru) |
MX (1) | MX2016004285A (ru) |
NZ (1) | NZ718148A (ru) |
SG (1) | SG11201602429QA (ru) |
TW (1) | TWI737576B (ru) |
WO (1) | WO2015049589A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016004285A (es) * | 2013-10-04 | 2016-07-08 | Engeneic Molecular Delivery Pty Ltd | Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. |
SG11201702627UA (en) * | 2014-10-03 | 2017-04-27 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
SG11201902940RA (en) * | 2016-10-06 | 2019-05-30 | Engeneic Molecular Delivery Pty Ltd | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
KR20240067973A (ko) | 2018-07-11 | 2024-05-17 | 액팀 테라퓨틱스, 인코퍼레이티드 | 조작된 면역자극성 박테리아 균주 및 이의 용도 |
JP2021532106A (ja) * | 2018-07-23 | 2021-11-25 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
SG11202107306WA (en) * | 2019-01-04 | 2021-08-30 | Engeneic Molecular Delivery Pty Ltd | Encapsulated glycolipid antigens for treatment of neoplastic diseases |
US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
JP2023518484A (ja) * | 2020-03-24 | 2023-05-01 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | コロナウイルス感染症を含むウイルス感染症を治療および/または予防するための組成物およびワクチン、並びにそれらの使用方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2315067B (en) | 1996-07-11 | 2000-02-16 | Pharmacia Spa | Morpholinyl anthracycline derivatives |
PL360581A1 (en) | 1999-05-11 | 2004-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
EP1231943A1 (en) * | 1999-11-12 | 2002-08-21 | Maxygen Holdings Ltd | Interferon gamma conjugates |
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
PT2302063T (pt) | 2001-10-15 | 2016-07-28 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo |
EP1594547A2 (en) * | 2003-02-14 | 2005-11-16 | University Of South Florida Research Foundation, Inc. | Chitosan-microparticles for ifn gene delivery |
US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
NZ547983A (en) * | 2003-12-09 | 2009-05-31 | Engeneic Molecular Delivery Pty Ltd | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
SI1718338T1 (sl) * | 2004-02-02 | 2015-09-30 | Engeneic Molecular Delivery Pty Ltd. | Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic |
CA2803995C (en) | 2004-08-26 | 2014-06-10 | Engeneic Molecular Delivery Pty Ltd. | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
AU2005276145C1 (en) | 2004-08-26 | 2011-01-06 | Engeneic Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
LT2712618T (lt) | 2006-06-23 | 2017-02-27 | Engeneic Molecular Delivery Pty Ltd. | Vaistų, terapinių nukleorūgščių ir funkcinių nukleorūgščių tikslinis įvedimas į žinduolio ląsteles per nepažeistas žuvusias bakterines ląsteles |
CN101715489B (zh) | 2007-03-30 | 2016-05-25 | 因詹尼克分子递送控股有限公司 | 用于体内递送至哺乳动物细胞的、包含无质粒的功能性核酸的、源自细菌的完整小细胞 |
ES2533710T3 (es) | 2010-12-02 | 2015-04-14 | Nerviano Medical Sciences S.R.L. | Proceso para la preparación de derivados de morfolinil antraciclina |
US9844598B2 (en) * | 2011-12-13 | 2017-12-19 | Engeneic Molecular Delivery Pty Ltd | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
AU2013327059B2 (en) * | 2012-10-02 | 2018-11-08 | Vaxiion Therapeutics, Llc | Immunomodulatory minicells and methods of use |
MX2016004285A (es) * | 2013-10-04 | 2016-07-08 | Engeneic Molecular Delivery Pty Ltd | Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. |
-
2014
- 2014-10-03 MX MX2016004285A patent/MX2016004285A/es unknown
- 2014-10-03 CN CN201480054853.1A patent/CN105658233B/zh active Active
- 2014-10-03 TW TW103134613A patent/TWI737576B/zh active
- 2014-10-03 WO PCT/IB2014/002824 patent/WO2015049589A1/en active Application Filing
- 2014-10-03 SG SG11201602429QA patent/SG11201602429QA/en unknown
- 2014-10-03 EP EP14851383.1A patent/EP3052122A4/en active Pending
- 2014-10-03 AU AU2014330895A patent/AU2014330895B2/en active Active
- 2014-10-03 EA EA201690680A patent/EA032740B1/ru unknown
- 2014-10-03 AP AP2016009153A patent/AP2016009153A0/en unknown
- 2014-10-03 BR BR112016007100A patent/BR112016007100A2/pt active Search and Examination
- 2014-10-03 JP JP2016519841A patent/JP6538031B2/ja active Active
- 2014-10-03 NZ NZ718148A patent/NZ718148A/en unknown
- 2014-10-03 KR KR1020167010107A patent/KR102433719B1/ko active IP Right Grant
- 2014-10-03 US US14/506,138 patent/US9731011B2/en active Active
- 2014-10-03 CA CA2926161A patent/CA2926161C/en active Active
-
2016
- 2016-03-31 IL IL244851A patent/IL244851B/en active IP Right Grant
- 2016-10-04 HK HK16111560.9A patent/HK1223281A1/zh unknown
-
2017
- 2017-07-28 US US15/663,562 patent/US10500277B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2014330895A1 (en) | 2016-04-14 |
CN105658233A (zh) | 2016-06-08 |
HK1223281A1 (zh) | 2017-07-28 |
US10500277B2 (en) | 2019-12-10 |
KR20160058885A (ko) | 2016-05-25 |
SG11201602429QA (en) | 2016-04-28 |
IL244851A0 (en) | 2016-05-31 |
US20150098897A1 (en) | 2015-04-09 |
AU2014330895B2 (en) | 2019-08-15 |
TWI737576B (zh) | 2021-09-01 |
KR102433719B1 (ko) | 2022-08-17 |
EP3052122A1 (en) | 2016-08-10 |
EA032740B1 (ru) | 2019-07-31 |
WO2015049589A1 (en) | 2015-04-09 |
IL244851B (en) | 2020-04-30 |
CA2926161C (en) | 2023-03-14 |
MX2016004285A (es) | 2016-07-08 |
AP2016009153A0 (en) | 2016-04-30 |
US20170326235A1 (en) | 2017-11-16 |
US9731011B2 (en) | 2017-08-15 |
NZ718148A (en) | 2022-02-25 |
JP2016532639A (ja) | 2016-10-20 |
CN105658233B (zh) | 2020-09-04 |
EP3052122A4 (en) | 2017-05-17 |
JP6538031B2 (ja) | 2019-07-03 |
TW201601748A (zh) | 2016-01-16 |
BR112016007100A2 (pt) | 2017-08-01 |
CA2926161A1 (en) | 2015-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690680A1 (ru) | Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма | |
MY197324A (en) | Adenovirus armed with bispecific t cell activator | |
MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
ZA201707869B (en) | Anti-ntb-a antibodies and related compositions and methods | |
PH12017500787A1 (en) | Methods of selecting t cell line and donor thereof for adoptive cellular therapy | |
MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
PH12016502132A1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
BR112017008972A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra carcinoma hepatocelular (hcc) e outros cânceres | |
MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
MA39907A (fr) | Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) | |
BR112016009402A2 (pt) | Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual | |
SV2017005355A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
MX2019010382A (es) | Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva. | |
SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
NZ609201A (en) | Means and methods for treating dlbcl | |
MX2016009284A (es) | Construcciones dirigidas a receptor y sus usos. | |
MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
WO2018009528A8 (en) | Combination cancer immunotherapies with arginine depletion agents | |
MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. | |
MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
SG194753A1 (en) | Induction of il-12 using immunotherapy |